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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neuron disease, and protein aggregation
has been proposed as a possible pathogenetic mechanism. However, the aggregate protein constituents are poorly
characterized so knowledge on the role of aggregation in pathogenesis is limited.
Methodology/Principal Findings: We carried out a proteomic analysis of the protein composition of the insoluble fraction,
as a model of protein aggregates, from familial ALS (fALS) mouse model at different disease stages. We identified several
proteins enriched in the detergent-insoluble fraction already at a preclinical stage, including intermediate filaments,
chaperones and mitochondrial proteins. Aconitase, HSC70 and cyclophilin A were also significantly enriched in the insoluble
fraction of spinal cords of ALS patients. Moreover, we found that the majority of proteins in mice and HSP90 in patients
were tyrosine-nitrated. We therefore investigated the role of nitrative stress in aggregate formation in fALS-like murine
motor neuron-neuroblastoma (NSC-34) cell lines. By inhibiting nitric oxide synthesis the amount of insoluble proteins,
particularly aconitase, HSC70, cyclophilin A and SOD1 can be substantially reduced.
Conclusion/Significance: Analysis of the insoluble fractions from cellular/mouse models and human tissues revealed novel
aggregation-prone proteins and suggests that nitrative stress contribute to protein aggregate formation in ALS.
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Introduction
Protein aggregation and deposits of abnormal proteins are
hallmarks of several neurodegenerative diseases [1]. In familial
forms the deposits frequently contain the mutant protein; in
sporadic forms, post-translational modifications of proteins may be
at the basis of the abnormal conformation. Aggregates are
biochemically poorly characterized and what is known of the
protein constituents comes essentially from immunohistochemistry
studies. This is probably why their role in neurodegeneration
remains poorly defined.
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
motor neuron disease, and protein aggregation has been proposed
as a possible pathogenetic mechanism [2]. Approximately 10% of
ALS cases are familial; 20% of these are associated with mutations
in the superoxide dismutase 1 (SOD1) gene. In SOD1-linked cases
it is thought that the mutant protein acquires new toxic properties,
such as the propensity to form aggregates [3,4]. The aggregation
hypothesis has received great support because mutant SOD1
mouse models of ALS develop protein inclusions in motor neurons
and in some cases in astrocytes. In addition, insoluble SOD1
complexes can start to be detected prior to disease onset [5,6].
Speculation has been offered on the mechanism of toxicity of
SOD1-rich aggregates. For example, they may sequester other
protein components essential for motor neuronal function, such as
chaperones and anti-apoptotic molecules [7], inhibit the ubiquitin-
proteasome system [8] and, by associating with motor proteins,
impair axonal transport [9]. Insoluble mutant SOD1 was found
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8130
associated with mitochondria and proposed as the basis of
mitochondrial dysfunction [10].
In sporadic and familial ALS patients the most widely observed
inclusions immunostain for ubiquitin, and other protein constituents
are largely unknown [11]. Immunohistochemistry studies have
detected proteins such as HSC70 [12], p38 MAP kinase [13] and
TDP-43 [14] as constituents of the inclusions in ALS patients. In
mutant SOD1 mice, protein inclusions are mainly immunoreactive
for SOD1 and ubiquitin but also contain HSC70 and p38 MAPK
[13]. We have shown that in the spinal cord of mice over-expressing
hSOD1, carrying the G93A mutation (G93A SOD1 mice), there is
progressive accumulation of mutant SOD1, its oligoubiquitinated
forms and other unknown proteins in the Triton X-100-insoluble
fraction (TIF) [5,15]. We have now used proteomic approaches to
characterize the protein composition of TIF, as a model of protein
aggregates, in G93A SOD1 mice at different stages of disease. We
identified several proteins enriched in TIF of ALS mice, most of
them nitrated. Interestingly, we already detected increased protein
nitration in the spinal cord soluble fraction of the G93A SOD1
mouse [16] and in the peripheral blood monuclear cells of ALS
patients [17]. We therefore investigated the role of nitrative stress in
aggregate formation in a cellular model of ALS and showed that by
inhibiting nitric oxide synthesis it is possible to interfere with
aggregation of proteins such as aconitase, HSC70, cyclophilin A
(CypA) and SOD1.
Results
In the spinal cord of G93A SOD1 mice we have observed
progressive accumulation of Triton-insoluble proteins: mutant
SOD1, its oligoubiquitinated forms and other unknown proteins
[5,15]. TIF from spinal cords of mutant mice are also enriched in
polyubiquitinated proteins (Figure S1), and therefore have the
fundamental biochemical features of protein inclusions in SOD1-
linked ALS. For these reasons TIF was used as our experimental
model of protein aggregates. In this study we characterized TIF of
the spinal cord of G93A SOD1 mice at different disease stages.
Proteomic Analysis of TIF from Spinal Cord of WT and
G93A SOD1 Mice with Advanced Disease
We started to analyze TIF from an advanced stage of disease, when
protein aggregates are most abundant. TIF averaged 3.660.7 mg
(n=5) per mg of spinal cord tissue in G93A SOD1 mice at the end
stage and 2.760.5 mg (n=5) in age-matched wild-type (WT) SOD1
mice (p,0.05, as assessed by Student’s t test). We analyzed the same
amounts of TIF from spinal cord of G93A SOD1 mice and age-
matched WT SOD1 mice by two-dimensional gel electrophoresis
(2DE). Figure 1 shows 2-D average maps of G93A and WT samples.
Gel images were analyzed and compared. The analysis detected
changes in protein composition of TIF in the two conditions. There
were 42 spots uniquely present in G93A samples (unmatched) and 94
Figure 1. 2DE proteomic analysis. Representative Sypro Ruby-stained 2DE maps of TIF of late-symptomatic G93A SOD1 mice (A) and age-
matched WT SOD1 mice (B). In panel A the numbered spots correspond to proteins enriched or only present in TIF of G93A samples, and in panel B
they indicate proteins enriched in TIF of WT samples. The same amount of protein was loaded in each gel (75 mg). The asterisk indicates the spot
corresponding to GFAP, which is the most prominent, but equally abundant in the two conditions, and was therefore considered as background.
doi:10.1371/journal.pone.0008130.g001
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spots with different volumes in G93A in comparison withWT samples;
62 were more present in G93A samples and 32 more present in WT
samples. We defined the proteins similarly present in both samples as
intrinsically poorly soluble in non-ionic detergents (the background),
and the ones enriched or only present in G93A samples as protein
aggregate constituents. After comparison of gel patterns 136
differentially present spots were excised from the gels and processed
for protein identification.
Identification of Differentially Present Proteins by MALDI-
TOF
Peptide mass fingerprinting spectra were recorded on a MALDI-
TOF mass spectrometer and proteins identified by a database
search using theMASCOT program. The proteins enriched or only
present in TIF from G93A samples are reported in Table 1 and
Table S1. They belong to different functional categories: cytoskel-
etal proteins, metabolic enzymes, mitochondrial proteins, chaper-
ones, proteins involved in signalling and mutant SOD1.MAPKp38,
previously found by immunohistochemistry in the inclusions in
spinal motor neurons of these mice [13], was enriched in TIF of
G93A SOD1 mice by Western blotting (WB) with the specific
antibody (Fig. 2). The most abundant protein spot in the 2D gels
(labelled with the asterisk in Fig. 1) was GFAP, which was not
differentially present. Fragments (spot 37,41,42,43,55,56) and a
high-Mw isoform (spot 5) of GFAP were instead specifically
enriched in G93A samples. Some proteins were more present in
TIF from WT mice and were therefore selected for protein
identification (Table S2). We could identify intermediate filament
proteins that are known to be enriched in TIF and more present in
WT samples since equal amounts of total proteins for WT and
G93A samples were loaded in the 2D gels. Clearly, the lower level of
neurofilaments in G93A samples is correlated with the consistent
motor neuron loss in G93A SOD1 mice with advanced disease.
Validation Analysis in Mouse and Human Spinal Cord
Samples
Some of the proteins enriched in TIF of G93A samples were
selected for validation by WB: HSP90, aconitase, HSC70, ERK2,
14-3-3 gamma, and CypA. Fig. 2 shows representative WB of the
same amounts of TIF from spinal cord of WT and G93A SOD1
mice probed with the specific antibodies. In all cases the
enrichment of the proteins analyzed by 2DE was confirmed by
WB (Fig. 2, Table S3). The levels of these proteins were also
measured in the soluble fraction. HSP90, aconitase, ERK1/2, 14-
3-3 gamma were similarly present in the soluble fraction of spinal
cord of WT and G93A SOD1 mice, while HSC70 and CypA,
abundantly expressed in neurons [18,19], were substantially lower
in G93A SOD1 mice, probably because of motor neuron loss.
TIF was also extracted from spinal cord tissues of sporadic ALS
patients and controls. Significantly more TIF was obtained from
patients than controls averaging 2.360.3 mg (n= 7) in comparison
with 1.760.5 mg (n= 3) per mg of tissue analyzed (p,0.05, as
assessed by unpaired t test with Welsh’s correction). The levels of
HSP90, aconitase, HSC70, ERK1/2 and CypA were measured by
dot blot analysis. Interestingly, CypA, aconitase, and HSC70 were
significantly enriched in TIF of patients (Fig. 3). The level of the
same proteins in the soluble fraction did not change (data not
shown).
DIGE Analysis of TIF from Spinal Cord of G93A SOD1 Mice
at Different Stages of Disease
We then measured the levels of aggregated proteins at earlier
disease stages, pre-symptomatic and early symptomatic. TIF from
spinal cord of G93A SOD1 mice at the three different stages was
analyzed by DIGE and compared with TIF from spinal cord of
WT SOD1 mice (Figure S2 and Table S4). Of the 66 protein spots
analyzed, 35 were more present in the G93A samples than in WT
already at 12 weeks of age, while 19 accumulated only at the end-
stage. For example, the neurofilament proteins L (NFL) and M
(NFM) accumulated in TIF of G93A SOD1 mice at 12 weeks of
age, while at end-stage disease the level of the insoluble proteins
fell, parallel with the motor neuron loss. Mitochondrial proteins
such as NADH-ubiquinone oxidoreductase and aconitase accu-
mulated at all ages as much as chaperone proteins, HSP90 and
HSC70. Insoluble 14-3-3 protein gamma was not recovered in
TIF of WT mice but was present at all ages in G93A SOD1 mice.
Proteins involved in glycolytic pathways, fructose-bisphosphate
aldolase C (aldolase C) and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), greatly accumulated, only or especially at end-
stage disease, as well as ERK2.
Immunohistochemistry of Aconitase
To verify the localization of proteins identified in the proteomic
screening, we did immunostaining analysis on spinal cord sections
of G93A SOD1 mice at pre-symptomatic and end stages of
disease. We selected aconitase that had no known prior association
with inclusions in ALS. Double labelling with anti-aconitase and
anti-cytochrome oxidase in the lumbar spinal cord of control
samples (Figure S3) showed that the punctate labelling of aconitase
and that of the mitochondrial marker cytochrome oxidase largely
overlapped in neuronal cell bodies and profiles scattered in the
neuropil. Aconitase immunoreactivity in human SOD1-labelled
motor neurons of WT SOD1 control mice (Fig. 4A–C) was similar
to that in non-transgenic mice (data not shown) and uniformly
distributed in small puncta around the nucleus. In contrast, in
human SOD1-labelled motor neurons of G93A SOD1 mice
aconitase immunoreactivity was found in large puncta already at
the pre-symptomatic stage of disease (Fig. 4D–F) and at the end
stage it occasionally co-localized with human SOD1 also in
neuropilar aggregates (Fig. 4G). Electron microscopy confirmed
that the anti-aconitase antiserum used selectively labelled mito-
chondria in spinal cord samples of control and transgenic mice
(Fig. 5). In the ventral horn of non-transgenic mice labelled
mitochondria were present in myelinated axons, cell bodies and
dendrites, close to unlabelled mitochondria (Fig. 5A, B, C). In
G93A SOD1 mice at both pre-symptomatic (Fig. 5D, E) and end-
stage (Fig. 5F–G) ages, an intense aconitase staining was found in
numerous mitochondria located in dendrites (Fig. 5D, E, G) and
cell bodies (Fig. 5F). Several labelled mitochondria appeared
swollen (Fig. 5E) and were frequently aggregated in clusters or
apposed at the inner membrane of vacuoles (Fig. 5D, G). Only in
end-stage G93A SOD1 mice the anti-aconitase antiserum also
labelled clumps of amorphous material scattered in the cytoplasm
of large neuronal cell bodies identifiable as motor neurons
(Fig. 5H).
The Majority of the Insoluble Proteins Are Tyrosine
Nitrated
We have previously shown a high level of protein nitration in
the soluble fraction of the spinal cord of G93A SOD1 mice already
at a pre-symptomatic stage of the disease, increasing as the disease
progresses [16]. We took into consideration that protein nitration
may be involved in the aggregation by altering the protein
structure and stability. We analyzed protein nitration in spinal
cord TIF at early symptomatic and end-stage disease. Figure 6
shows a representative 2D WB of TIF from early symptomatic
G93A SOD1 mice probed with anti-nitrotyrosine polyclonal
Insoluble Proteins in ALS
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Table 1. Proteins enriched in TIF of spinal cord from G93A SOD1 mice at 26 weeks of age compared to age-matched WT SOD1
mice.
Spot Protein name WTa G93Ab FCc
Cytoskelton
5 Glial fibrillary acidic protein (GFAP)* - 1.760.3
20 Vimentin* - 3.961.1
56 GFAP# 0.860.1 2.960.6 3.6
58 Neurofilament triplet M protein# (NFM) 0.960.4 2.361.0 2.5
42 GFAP# 0.860.2 1.860.1 2.2
36 Vimentin# 1.560.1 3.061.0 2.0
31 Vimentin 47.667.1 78.6614 1.7
37 GFAP# 5.260.2 8.360.9 1.6
55 GFAP# 1.760.3 2.860.7 1.6
41 GFAP# 3.260.4 4.860.6 1.5
43 GFAP# 4.160.6 6.260.6 1.5
Metabolism
32 Alpha enolase - 1.160.3
33 Alpha enolase - 0.860.3
39 Glutamine synthetase - 0.760.2
40 Aspartate aminotransferase - 0.660.1
46 Fructose-bisphosphate aldolase C (aldolase) - 0.460.1
49 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) - 2.360.5
51 L-lactate dehydrogenase B chain (LDH) - 2.960.6
26 Pyruvate kinase isozyme M2 0.260.1 2.760.7 13.5
25 Pyruvate kinase isozyme M2 0.360.0 2.460.4 8.0
52 Cytosolic malate dehydrogenase 0.360.2 1.460.2 4.7
48 GAPDH 0.660.1 2.860.6 4.6
47 GAPDH 0.560.3 1.960.3 3.8
38 Glutamine synthetase 0.360.0 0.860.3 2.7
Mitochondria
9 NADH-ubiquinone oxidoreductase - 1.660.6
10 Glycerol-3-phosphate dehydrogenase - 0.360.1
12–13 Aconitase - 0.460.1
14 Aconitase - 0.360.0
35 Creatine kinase - 0660.2
44 Isocitrate dehydrogenase [NAD] - 0.660.0
34 Creatine kinase 0.260.1 1.060.2 5.0
30 ATP synthase alpha chain (ATPase) 0.660.0 2.360.6 3.8
11 Aconitase 0.260.1 0.660.1 3.0
50 Pyruvate dehydrogenase E1 1.460.3 3.760.3 2.6
27 Glutamate dehydrogenase 1 0.360.0 0.760.1 2.3
28 Glutamate dehydrogenase 1 0.360.1 0.760.1 2.3
29 ATPase 0.560.1 1.160.2 2.2
Chaperones
8 Heat shock protein 90-alpha (HSP90) - 1.260.1
59 Alpha crystallin B chain - 1.760.6
60 Alpha crystallin B chain - 5.861.6
61 Peptidyl-prolyl cis-trans isomerase A (CypA) - 0.460.1
57 Heat-shock protein beta-1 (HSP27) 0.760.1 3.260.9 4.7
17 Heat shock cognate 70 kDa protein (HSC70) 10.062.2 16.464 1.6
Signaling
53 Annexin A5 - 1.160.2
Insoluble Proteins in ALS
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antibody. Similar results were obtained with the monoclonal anti-
nitrotyrosine antibody. Surprisingly, the majority of the protein
spots in TIF, 39 out of 69 (Table 2), were nitrated and gave a very
intense signal (Fig. 6A), especially the mitochondrial protein
aconitase (spots 11,12,13,14), HSC70 (spot 17) and the interme-
diate filament proteins, NFL (spot 16), alpha-internexin (spot 21),
vimentin (spot 31) and GFAP (spot c); NFM (spot 1,4) and NFH
(spot 2), although abundant (Fig. 6B), were only mildly nitrated
(Fig. 6A). Nitrated proteins in TIF from WT SOD1 samples were
hardly detected (Figure S4). To check whether there is a parallel
with the human disease, the level of nitrated HSP90 (spot 8 in the
mouse experiment), for which a specific antibody is available [20],
was measured in the TIF of sporadic ALS patients and controls by
dot blot analysis. Interestingly, the TIF of ALS patients showed
enrichment of the nitrated protein (Fig. 6C). The level of nitrated
HSP90 in the soluble fraction was not changed (data not shown).
L-NAME Reduces the Level of Detergent-Insoluble
Proteins in a Cellular Model of fALS
To investigate whether protein nitration has a causative role in
aggregate formation or is just a consequence of the longer exposure of
protein inclusions to oxidative stress, we used the NSC-34 cell line
expressing G93A hSOD1, or WT hSOD1 as control. These cells did
not produce evident aggregates under basal conditions, however they
were induced to accumulate insoluble proteins by treatment with a
proteasome inhibitor (MG132), similarly to previous findings [21].
Under these conditions double the amount of TIF was isolated from
WT and G93A SOD1 expressing cells compared to untreated cells
(Fig. 7A). The cellular TIF from mutant SOD1 cells had the
biochemical features of the one isolated from the spinal cord of mutant
SOD1 mice: high levels of mutant SOD1 (Fig. 7G), nitrated proteins
(Fig. 7B) and ubiquitinated proteins (data not shown). This enabled us
Spot Protein name WTa G93Ab FCc
54 14-3-3 protein gamma 1.160.2 3.961.1 3.4
45 ERK2 0.360.04 0.960.2 2.7
Endoplasmic reticulum
6 Endoplasmin - 2.660.5
7 Transitional endoplasmic reticulum ATPase - 5.961.3
18 Protein disulfide-isomerase (PDI) - 2.460.4
Others
62 SOD1 - 0.960.1
63 SOD1 - 3.360.3
64 SOD1 - 8.461.1
65 SOD1 - 14.562.2
66 SOD1 - 1.660.2
23 Dihydropyrimidinase-related protein 2 0.761.3 1.460.4 2.0
24 Dihydropyrimidinase-related protein 2 0.860.0 1.660.3 2.0
22 Dihydropyrimidinase-related protein 2 0.860.2 1.560.4 1.9
The proteins are categorized by their known function, in bold are the ones only found in G93A samples, the others are sorted by their fold change from highest to
lowest.
aWT, normalized spot volumes of the WT sample, mean of three replicates6SD.
bG93A, normalized spot volumes of the G93A samples, mean of three replicates6SD.
cFC, fold change of spot volume as ratio of the spot volumes (G93A/WT); the value is missing for proteins only found in G93A samples.
-spot not detected in WT samples.
*Mr higher than expected, unknown protein modification.
#Mr lower than expected, possible protein fragment.
doi:10.1371/journal.pone.0008130.t001
Table 1. Cont.
Figure 2. Immunoblot validation of TIF in mouse samples.
Representative immunoblot of TIF and corresponding soluble fraction
from spinal cord of late-symptomatic G93A SOD1 mice and age-
matched WT SOD1 mice. Same amounts of TIF and soluble proteins
(30 mg) were loaded in each immunoblot and probed with the specific
antibodies. Immunoreactivity was normalized to the actual amount of
protein loaded as detected after Coomassie blue staining.
doi:10.1371/journal.pone.0008130.g002
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to examine the ab initio aggregate formation of some of the proteins
found in the TIF of the mice, also present in the cellular TIF. We
measured the effect of a non-selective nitric oxide synthase (NOS)
inhibitor, L-NAME, on the insolubility of aconitase and HSC70,
nitrated in the mice, CypA and SOD1, susceptible to other types of
oxidative modifications [22–24], and nitrated HSP90 (Fig. 7C–G).
Fig. 7A–B shows that L-NAME reduced the total MG132-induced
TIF in NSC-34 cells expressing G93A SOD1 by 56% and this
reduction paralleled the reduction of nitrated proteins (52%).
Specifically, L-NAME reduced the amount of nitrated HSP90 by
81%, aconitase by 72%, HSC70 by 86%, CypA by 91% and SOD1
by 61% in TIF of G93A SOD1 NSC-34 cells (Fig. 7C–G). L-NAME
also had an effect in TIF isolated from G93A SOD1 cells under basal
conditions, and although small it was significant for nitrated HSP90
and aconitase (Fig. 7C,D). The reduction of MG132-induced TIF in
WT SOD1 cells was smaller, 18%, and was never significant for the
single proteins analyzed. It is noteworthy that MG132 alone did not
raise the level of nitrated proteins inTIF fromWTSOD1 cells (Fig. 7B).
These data suggest that the increase in nitrated proteins in G93A
SOD1 cells has to be attributed to the increased oxidative/nitrative
stress caused, directly or indirectly, by mutant SOD1 [25–28]. The L-
NAME treatment was therefore effective only in G93A SOD1 cells
possibly because only there oxidative/nitrative stress played a role in
the formation and consolidation of the aggregates. We measured cell
Figure 3. Immunoblot validation of TIF in human samples. Dot
blot analysis of TIF in spinal cord tissues of sporadic ALS patients (n = 7),
black bars, and controls (CTR) (n = 3), white bars. Total TIF is the ratio of
the amount of TIF to the total proteins extracted. Proteins were
quantified by the BCA protein assay. The same amount of TIF (3 mg) was
loaded on the membrane and probed with the specific antibodies.
Histograms represent the immunoreactivity normalized to the actual
amount of protein loaded, detected after Red Ponceau staining. Values
are percentages of controls and are the mean6SD. *, significantly
different from controls as assessed by unpaired t test with Welsh’s
correction (p,0.05).
doi:10.1371/journal.pone.0008130.g003
Figure 4. Immunohistochemistry of aconitase. Immunolabelling
for aconitase (A, C, D, F, G, green) and human SOD1 (B, C, E–G, red) in
ventral horn lumbar spinal cord sections from a 26-week-old control WT
SOD1 mouse (A–C) and G93A SOD1 mice at 12 (D–F) and 26 (G) weeks.
C, F, G are merged images. In controls the human SOD1-expressing
motor neurons show fine punctate aconitase labelling (A–C), whereas in
presymptomatic G93A SOD1 mice the motor neurons expressing
mutant human SOD1 show large aggregates of aconitase (D, arrows)
only partially overlapping SOD1-positive aggregates (F). In end-stage
G93A SOD1 mice (G) aggregates of aconitase and SOD1 are present in
large vacuolated (v) motor neurons and also in the surrounding
neuropil (double arrows); n, nuclei; v, vacuoles. Bar = 40 mm.
doi:10.1371/journal.pone.0008130.g004
Insoluble Proteins in ALS
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death by quantifying extracellular LDH activity in cells lines expressing
WT and G93A SOD1, treated with MG132, L-NAME or both
(Fig. 7H). As expected, MG132 was toxic on both cell lines, but was
significantly more toxic in G93A SOD1 expressing cells. Interestingly,
L-NAME in combination with MG132 partially rescued cells from
MG132-induced toxicity, reducing cell death by respectively 16% and
13% in WT and G93A cells.
Discussion
We previously reported that mutant SOD1 and its oligoubi-
quitinated forms are abundantly recovered in TIF of the spinal
cord from G93A SOD1 mice [5]. However, from that study we
deduced that there were several unknown proteins in addition to
mutant SOD1. The present proteomic analysis enabled us to
identify 66 protein spots exclusively present or more abundant
in TIF of ALS mice than controls. To our knowledge, this is the
first successful large-scale analysis of detergent-insoluble pro-
teins in an ALS mouse model. This was possible because of the
use of an optimized 2DE-based proteomic approach to isolate
and analyze TIF. A previous attempt, based on liquid
chromatography-electrospray ionization mass spectrometry,
found primarily SOD1 and only traces of other abundant
proteins [29].
Figure 5. Ultrastructural localization of aconitase. Immunolabelling in the ventral horn of non-trasgenic control mice at 26 weeks of age (A–C)
and of G93A SOD1 mice at pre-symptomatic (12 weeks, D–E) and end-stage (26 weeks, F–G) of disease. In controls labelling is in mitochondria (m)
located in axons (A), cell bodies (B) and dendrites (C). In G93A SOD1 mice intensely labelled mitochondria (m) are clustered together in dendrites (D)
and cell bodies (F), swollen (E) and apposed at the membrane of vacuoles (v) (D, G). Occasional clumps of aconitase-positive material (arrows) are
found in end-stage motor neurons (H). N, Nucleus; nu, nucleolus. Bars: A–C, E = 1 mm; D, F = 2,5 mm; G= 1,2 mm; H= 1,4 mm.
doi:10.1371/journal.pone.0008130.g005
Insoluble Proteins in ALS
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8130
It is known that mutant SOD1 forms aggregates in different
cellular compartments such as mitochondria [10], endoplasmic
reticulum [30] and perykaria [31]. We found insoluble proteins
from these subcellular compartments, and showed that many of
these proteins start to aggregate already at a presymptomatic stage
of the disease as much as mutant SOD1 [5].
Intermediate filaments such as neurofilaments, vimentin and
GFAP were the most abundant proteins recovered in TIF of WT
and G93A SOD1 mice. However, high-Mw isoforms of NFM,
NFL, vimentin and GFAP were only found in TIF of ALS mice.
These may be ubiquitinated forms, but because of their low
abundance we were not able to identify the modification by mass
spectrometry. Immunocolocalization of ubiquitin and neurofila-
ments has already been observed in neuronal hyaline inclusions in
G93A SOD1 mice and ALS patients [32,33]. Fragments of
intermediate filaments already accumulated at a pre-symptomatic
stage of the disease. GFAP and NFL fragments have been
observed in spinal cords of ALS patients [34,35] and this may
indicate increased activation of specific proteases or oxidation-
induced protein fragmentation [36].
Several enzymes important in energy metabolism were also
present. Their aggregation may explain the defective mitochon-
drial respiratory chain activities and ATP production in the
mutant mice [37]. While glycolytic enzymes are highly recovered
mainly at symptomatic stages of disease, insoluble mitochondrial
enzymes already accumulate at a pre-symptomatic stage. This
Figure 6. Analysis of nitrated proteins in TIF of 17-week-old G93A SOD1 mice. 150 mg of TIF was loaded into the 2D gel and transferred
onto a PDVF membrane. The blot was probed with anti-nitrotyrosine polyclonal antibody (A), after total protein SYPRO Ruby blot staining (B).
Nitrated protein signals of the 2D WB were matched and localized in a twin 2D gel and proteins were identified by peptide mass fingerprinting. Spot
numbers in (A) correspond to proteins in Table 2. a, b and c are spots corresponding respectively to laminin subunit beta-2, VDAC, GFAP, that were
not specifically increased in G93A TIF in the proteomic screening. (C) Dot blot analysis of nitrated HSP90 in TIF of spinal cord tissues of controls (CTR)
(n = 3), white bars, and sporadic ALS patients (n = 7), grey bars. The same amount of TIF (3 mg) was loaded on the membrane and probed with the
specific antibody. Histograms represent the immunoreactivity normalized to the actual amount of protein loaded, as detected after Red Ponceau
staining. Values are percentages of controls and are the mean6SD. *, significantly different from controls as assessed by unpaired t test with Welsh’s
correction (p,0.05). Representative dot blots for a control and an ALS patient are reported.
doi:10.1371/journal.pone.0008130.g006
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agrees with the observations of early alterations of mitochondria
[38] and the presence of SOD1-rich aggregates in mitochondria of
ALS mice [10]. Among the mitochondrial enzymes, mitochondrial
aconitase, which is altered in aging and neurodegenerative diseases
it is of special interest [39,40]. The enzyme is highly sensitive to
oxidative inactivation and modifications [41]. We have reported
that aconitase is susceptible to tyrosine nitration, as detected in the
soluble fraction of the spinal cord of pre-symptomatic G93A
SOD1 mice [16]. In this study, we found it was abundantly
recovered, highly nitrated, in TIF. Accumulation is substantial
already before the onset of disease, as confirmed by immuno-
staining analysis on spinal cord sections. In some cases it co-
localized with SOD1, however it is likely that it can aggregate also
independently from G93A SOD1. Accumulation of the insoluble
protein was also detected in spinal cord tissues of sporadic ALS
patients. This confirms a mitochondrial alteration in the animal
model and in patients. It also candidates aconitase as a sensitive
biomarker of the human disease.
One of the functional categories highly present in our analysis is
the chaperone. Chaperones are potent controllers of protein
aggregation, promoting protein folding and refolding, and
cooperating to degrade irreversibly damaged proteins. They were
greatly enriched in TIF of G93A SOD1 mice early in the disease
and, except for HSC70, absent or scant in WT SOD1 mice. A
specific interaction between chaperones and mutant SOD1, but
not WT SOD1, is also indicated in other works [42,43].
Chaperone activity has been reported to be reduced in spinal
cord of G93A and G85R SOD1 mice before the disease onset
[44]. One possibility is that chaperones are sequestered by
misfolded mutant SOD1, so are less available for cytoprotective
functions. This notion is borne out by the fact that increasing
expression of HSP70 by gene transfer protected cultured motor
neurons from mutant SOD1 toxicity [45], although overexpress-
ing only HSP70 was not effective in vivo [46]. As suggested by our
analysis, which found several chaperones damaged, upregulating a
panel of such proteins is likely to be a more successful
pharmacological strategy.
Proteins involved in signalling were also enriched early in the
disease. 14-3-3 protein gamma is a protein adaptor that recognize
the phosphoserine-containing motif of several target proteins and
regulates signal transduction pathways. 14-3-3 proteins have been
found in Lewy body-like hyaline inclusions in ALS patients [47].
These proteins may recognize the phosphorylated serine residues
of neurofilaments and promote their abnormal accumulation, or
remain entrapped in the inclusions. A similar situation may arise
with ERK. ERK1/2 are MAP kinases, which are activated by
various mechanisms and have more than 100 different substrates,
including NFM, NFH and alpha crystalline [48]. It is possible that
ERK1/2 are aberrantly activated and sequestered with the
substrates in the aggregates. Finally, TDP-43 was not found
among the aggregated proteins in the G93A SOD1 mice, as
already reported in another study [49].
What is peculiar is that most of the proteins found in TIF are
intrinsically soluble and stable with no apparent reason to be co-
purified with insoluble mutant SOD1. The high affinity of
chaperones for mutant misfolded SOD1 only partially explains
the molecular determinants of aggregation. We have shown that
the level of proteins carrying an oxidative modification, tyrosine
nitration, possibly induced by mutant SOD1 [25,26], are
increased in the spinal cord soluble fraction of G93A SOD1 mice
already at a pre-symptomatic stage of disease [16]. Interestingly,
some of these nitrated proteins were also recovered in TIF,
including HSC70, alpha enolase and ATPase. Nitrated NFL has
been shown to inhibit the assembly of unmodified neurofilament
subunits and therefore may be at the basis of neurofilament
aggregate formation [50]. Nitrated alpha synuclein and tau have
been found in brain of patients with Parkinson’s and Alzheimer’s
diseases [51,52]. However, in vitro, at least for alpha synuclein, the
impact of nitration on aggregation is controversial [53,54].
Since no comprehensive study of the nitration pattern of
insoluble proteins has ever been done, it was not possible to
consider protein nitration as a potential general mechanism of
protein aggregation. By using a proteomic approach we
demonstrated that the majority of the proteins enriched in TIF
of the ALS mouse was nitrated. In human tissues at least one
nitrated protein, HSP90, was detected enriched in TIF of sporadic
ALS patients. Thus nitration might have some role in aggregate
formation in ALS. Nevertheless, from such experiments ex vivo we
could not establish whether nitration was a consequence of the
Table 2. Nitrated proteins in TIF of spinal cord of G93A SOD1
mice.
Spot Protein name
Cytoskeleton
1 NFM*
2 NFH
4 NFM
16 NFL
19–20 Vimentin*
21 Alpha-internexin
31 Vimentin
Metabolism
25–26 Pyruvate kinase isozyme M2
32–33 Alpha enolase
38–39 Glutamine synthetase
47–48–49 GAPDH
51 LDH
Mitochondria
10 Glycerol-3-phosphate dehydrogenase
11–12–13–14 Aconitase
27–28 Glutamate dehydrogenase 1
29–30 ATPase
34–35 Creatine kinase
Chaperones
8 HSP90
17 HSC70
59–60 Alpha crystallin B chain
Endoplasmic reticulum
6 Endoplasmin
7 Transitional endoplasmic reticulum ATPase
18 PDI
Others
22–23–24 Dihydropyrimidinase-related protein 2
a Laminin subunit beta-2
b VDAC1
c GFAP
*Mr higher than expected, unknown protein modification; a, b, c, proteins not
specifically enriched in TIF of G93A mice.
doi:10.1371/journal.pone.0008130.t002
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longer life-time of proteins entrapped in the inclusions. Using a
NSC-34 cell model of ALS we demonstrated that inhibiting
nitrative stress by treatment with a non-selective NOS inhibitor, L-
NAME, substantially reduced the amount of MG132-induced
insoluble proteins. This confirms a previous study showing that
treatments with a proteasome inhibitor of cell lines expressing
mutant SOD1 decreased aggregation of certain proteins [21],
strengthening the hypothesis that nitration plays a role in
aggregation. More specifically, we detected reduced levels of
insoluble nitrated HSP90, aconitase and HSC70, nitrated in the
mouse samples, CypA and SOD1, susceptible to cysteine thiol
modifications [24,55,56]. Inhibition of NO synthesis leads to a
decrease in peroxynitrite formation, which in turn may reduce
tyrosine nitration but also various cysteine oxidations, including
disulfides and nitrosothiols. We therefore propose that L-NAME
interferes more generally with oxidative modification-induced
protein aggregation in the presence of mutant SOD1. Under this
condition the reported decrease in the level of endogenous
Figure 7. Analysis of TIF of NSC-34 cells expressing WT and G93A hSOD1, treated or not with MG132, L-NAME or both. (A) Total TIF is
the ratio of the amount of TIF to the total proteins extracted. Proteins were quantified in each condition by the BCA protein assay. Values are
percentages of the untreated WT control and are the mean6SEM (n= 3). (B–G) The level of nitrotyrosine, nitrated HSP90 (HSP90NT), aconitase, HSC70,
CypA and SOD1 were measured by dot blot analysis. The same amount of cellular TIF (3 mg) was loaded on the membrane and probed with the
specific antibodies. Histograms represent the immunoreactivity normalized to the actual amount of protein loaded, as detected after Red Ponceau
staining, multiplied by the total TIF isolated for each condition. Values are percentages of the untreated WT control and are the mean6SEM (n= 3).
*, significantly different from untreated G93A controls (p,0.05); **, significantly different from MG132-treated G93A samples (p,0.05);
***, significantly different from MG132-treated WT samples (p,0.05), as assessed by one-way ANOVA followed by Newman-Keuls multiple
comparison test. (H) Analysis of cell death by quantification of extracellular LDH activity. Histograms represent mean6SD of four replicates. One-way
ANOVA was followed by Newman-Keuls multiple comparison test. *, p,0.05.
doi:10.1371/journal.pone.0008130.g007
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antioxidants might play a role [28,57]. However, in this cell
paradigm we could not really evaluate the effect of reduced protein
aggregation on cell viability. L-NAME only partially rescued cells
from MG132 treatment, which is highly toxic at the concentration
used to induce aggregate formation. It has been reported that in
vivo treatments with NOS inhibitors were protective in animal
models of motor neuron degeneration, but in other studies they
were ineffective [58–60]. Although the role of NOS and the use of
NOS inhibitors for therapeutic purposes is debated [59,61,62], our
data provide additional indications of the importance of aiming
pharmacological approaches at pathways that modulate nitrative
stress which, if regulated as early as possible, may influence
downstream aggregation pathways too.
In conclusion, a striking difference between WT and G93A
SOD1 mice is in TIF and consists in the portion of the proteome
that, damaged or altered in pathological conditions, loses its
structural determinants and accumulates as insoluble material as
the disease progresses. Some components of this insoluble fraction
are also found in sporadic ALS patients suggesting that they could
be novel markers of the human sporadic forms. Finally,
characterization of tyrosine nitrated insoluble proteins showed
that nitrative stress, induced by SOD1 mutation or other unknown
instigation factor(s) in the case of the sporadic forms, may
contribute to protein aggregate formation in ALS.
Materials and Methods
Transgenic Mice
Transgenic G93A SOD1 mice originally obtained from Jackson
Laboratories and expressing about 20 copies of mutant human
(h)SOD1 with a Gly93Ala substitution (B6SJL-TgNSOD-1-
SOD1G93A-1Gur), or WT hSOD1 were bred and maintained
on a C57BL/6 genetic background at Harlan Italy S.R.L., Bresso
(MI), Italy. Transgenic mice were identified by PCR. The mice
were housed at 2161uC with 55610% relative humidity and 12 h
light. Food (standard pellets) and water were supplied ad libitum.
Female G93A SOD1 mice were sacrified at pre-symptomatic (12
weeks of age), early symptomatic (17 weeks of age) and end-stages
(26 weeks) of the disease. Female non transgenic littermates and
WT SOD1 mice at 26 weeks of age were used as controls.
Procedures involving animals and their care were conducted in
conformity with the institutional guidelines that are in compliance
with national (D.L. No. 116, G.U. Suppl. 40, Feb. 18, 1992,
Circolare No. 8, G.U., 14 luglio 1994) and international laws and
policies (EEC Council Directive 86/609, OJ L 358,1, Dec.12,
1987; NIH Guide for the Care and Use of Laboratory Animals,
U.S. National Research Council, 1996).
Human Samples
Frozen spinal cord from controls and ALS patients were partly
from the Netherlands Brain Bank (NBB), Netherlands Institute for
Neuroscience, Amsterdam, and partly provided by Michael
Strong, Robarts Research Institute, London, Ontario. Post-
mortem delay of the control subjects was ,12 h and of ALS
patients was ,12 h (n= 3), ,24 h (n= 4). No abnormalities were
detectable at autopsy in the spinal cord tissues of the three controls
who died due to cardiac arrest, cancer and pneumonia. All ALS
cases were negative for mutations in TDP-43 and SOD1. Table S5
reports the clinical and neuropathological characteristics of the
ALS cases. All material has been collected and used in compliance
with the ethical and legal declaration of the Netherlands Brain
Bank and Robarts Research Institute after a written informed
consent from donor or legal representative.
Extraction of Detergent-Insoluble Protein
Tissues were processed as previously described [5]. Briefly,
they were homogenized in ice-cold homogenisation buffer,
pH 7.6, containing 15 mM Tris-HCl, 1 mM DTT, 0.25 M
sucrose, 1 mM MgCl2, 2.5 mM EDTA, 1 mM EGTA, 0.25 M
sodium orthovanadate, 2 mM sodium pyrophosphate, 5 mM
MG132 proteasome inhibitor (Sigma), 1 tablet of CompleteTM/
10 mL of buffer, Mini Protease Inhibitor Mixture (Roche Applied
Science). The samples were centrifuged at 100006g at 4uC for 15
minutes, obtaining a supernatant (S1) and a pellet. The pellet was
suspended in ice-cold homogenisation buffer with 2% of Triton
X-100 and 150 mM KCl, sonicated three times for 10 sec and
shaken for 1 hour at 4uC. Samples were then centrifuged twice at
100006g at 4uC for 10 minutes to obtain Triton X-100-resistant
pellets (TIF) and a supernatant (S2). The soluble fraction is
considered the pool of S1 and S2 fractions. Proteins were
quantified by the Bradford assay. To isolate TIF from human
spinal cords, tissues were cut with a cryostat microtome and the
sections were collected in a tube containing 10 volumes (w/v) of
homogenisation buffer and processed as described for the mice
tissues. To isolate TIF from cells the protocol was slightly
modified. Briefly, cells were directly lysed in 0.2% of Triton X-
100 and 150 mM KCl, sonicated and shaken for 1 hour at 4uC.
Samples were then centrifuged at 100,0006g for 1 hour. The
pellets were boiled in 50 mM Tris HCl pH 6.8 and SDS 2% and
analyzed. Proteins were quantified by the BCA protein assay
(Pierce).
2DE
Samples were dissolved in 7 M urea, 2 M thiourea, 4% (w/v)
CHAPS, 0.5% (v/v) IPG buffer (GE Healthcare) and 12 mg/mL
DeStreakTM Reagent (GE Healthcare). Samples were pools of TIF
from five mice for each genotype. Aliquots of 75 mg were loaded in
each 2D gel by in-gel rehydration (1 h at 0 V, 270 Vhr at 30 V)
on pH 3-10 non-linear 7-cm IPG strips (GE Healthcare). IEF was
done on an IPGphor (GE Healthcare) according to the following
schedule: 200 Vhr at 200 V, 925 Vhr of a linear gradient up to
3500 V, 10500 Vhr at 3500 V, 14375 Vhr of a linear gradient up
to 8000 V, 48000 Vhr at 8000 V. Strips were then re-equilibrated
in NuPAGE LDS Sample Buffer (Invitrogen) and second
dimension was run on precast, 4–12% polyacrylamide gradient
gel, NuPAGEH Bis-Tris (Invitrogen). Gels were stained with
SYPROH Ruby protein gel stain (Invitrogen).
2D Image Analysis and Quantification
Changes in protein spot volumes were calculated comparing
gels from pools of five samples, from 26-week-old WT and G93A
SOD1 mice, run in triplicate. Gel images were captured by the
laser scanner Molecular ImagerH FX (Bio-Rad) and 2D image
analysis was done with Progenesis PG240 v2006 software
(Nonlinear Dynamics). The analysis protocol for the gel images
included: spot detection, warping, background subtraction,
averaged gel creation, matching and reference gel modification.
Detection, warping, and matching of the protein spots were done
using the ‘‘combined warp and match’’ algorithm, which uses a
nonparametric pattern recognition clustering technique to align
different gel images. The ‘‘Total spot volume normalization’’
algorithm was used to calculate each protein spot volume as the
sum of the intensities of the pixels within the spot’s boundary,
minus the background level within that same boundary,
normalized to the total spot volumes in the gel. Observed pI
and Mr were calculated by the software based on protein spots of
known characteristics.
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Protein Identification
Protein spots were located and excised with an EXQuestTM spot
cutter (Bio-Rad). Spots were processed and gel-digested with
trypsin, as previously described [16]. Tryptic digests were
concentrated and desalted using ZipTip pipette tips with C18
resin and 0.2 ml bed volume (Millipore). Peptide mass fingerprint-
ing was done on a ReflexIIITM MALDI-TOF mass spectrometer
(Bruker Daltonics) equipped with a SCOUT 384 multiprobe inlet
and a 337-nm nitrogen laser using a-cyano-4-hydroxycinnamic
acid as matrix, prepared as previously described [63]. All mass
spectra were obtained in positive reflector mode with a delayed
extraction of 200 ns. The reflector voltage was set to 23 kV and
the detector voltage to 1.7 kV. All the other parameters were set
for an optimized mass resolution. To avoid detector saturation
low-mass material (500 Da) was deflected. The mass spectra were
internally calibrated with trypsin autolysis fragments. The mass
spectra were obtained by averaging 150–350 individual laser shots
and then automatically processed by the FlexAnalysis software,
version 2.0 using the following parameters: the Savitzky Golay
smoothing algorithm and the SNAP peak detection algorithm.
Database searches (Swiss-Prot, release 57.3, June 2009) were done
using the Mascot software package available on the net (http://
www.matrixscience.com), allowing up to one missed trypsin
cleavage, carbamidomethylation of Cys and oxidation of Met, as
variable modifications, and a mass tolerance of 60.1 Da over all
Mus musculus protein sequences deposited. A protein was regarded
as identified if the following criteria were fulfilled: the probability-
based MOWSE [64] score was above the 5% significance
threshold for the database and the spots excised from at least
two different gels gave the same identification.
DIGE Analysis
The four experimental groups were: G93A SOD1 mice at 12,
17 and 26 weeks of age and WT SOD1 mice at 26 weeks of age.
Equal amounts of TIF from spinal cords of five mice from each
group were pooled. Samples were labelled according to the
manufacturer’s instructions (GE Healthcare) with minor modifi-
cations. Briefly, 25 mg of each pool was labelled with 200 pmol of
Cy3 or Cy5 dye for 30 min in ice in the dark. To exclude
preferential labelling of the dyes, each sample was also reverse
labelled. As an internal standard, aliquots of each pool were mixed
and labelled with Cy2 dye. Four 2D gel were run as described in
the 2DE section. Each gel contained two experimental groups, one
Cy3-labelled, the other Cy5-labelled plus the Cy2-labelled internal
standard. Gel images were captured by the laser scanner
Molecular Imager FX (Bio-Rad). Image analysis was done with
Progenesis PG240 v2006 software (Nonlinear Dynamics). The
spots analyzed were those that were differentially expressed in the
end-stage analysis. For each spot the normalized volume was
standardized against the intra-gel standard, dividing the value for
each spot normal volume by the corresponding internal standard
spot normal volume within each gel. The values for each spot in
each group were expressed as mean the of the values from the
Cy3- and Cy5-labelled analyses.
WB
Proteins were transferred onto PVDF membranes (Millipore).
For the reaction with the primary antibodies, membranes were
incubated for 1 h at room temperature with a blocking buffer (5%
milk in Tris-buffered saline containing 0.1% Tween 20) and
probed overnight at 4uC. Primary antibodies were: rabbit
polyclonal anti-mitochondrial aconitase (1:2500), kindly provided
by Dr. L.I. Szweda [65], rabbit polyclonal anti-14-3-3 protein
gamma (1:2000), kindly provided by Dr. F. Tagliavini, rabbit
polyclonal anti-heat shock protein 90 (HSP90) (1:1000) from
Stressgen, mouse monoclonal anti-heat shock cognate 70 kDa
protein (HSC70) (1:1000) from Santa Cruz Biotechnology, mouse
monoclonal anti-neurofilament triplet L protein (NFL) (1:1000)
and rabbit polyclonal anti-CypA (1:2500) from Upstate, rabbit
polyclonal anti-ERK1/2 (1:1000), rabbit polyclonal anti-MAP
kinase p38 (MAPKp38) (1:1000) from Cell Signaling, and rabbit
polyclonal anti-ubiquitin (1:800) from DAKO. The blots were
probed with goat anti-rabbit or anti-mouse peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology) and developed
by the ECL Plus protein detection system (GE Healthcare) or
Immobilon Western Chemiluminescent HRP Substrate (Millipore)
on the ChemiDoc XRS system (Bio-Rad). Densitometry was done
with Progenesis PG240 v2006 software (Nonlinear Dynamics).
Immunoreactivity was normalised to the actual amount of proteins
loaded on the membrane as detected after Coomassie Blue
staining.
Analysis of TIF from Human Samples
Total TIF is considered the ratio of the amount of isolated TIF
to the total proteins extracted. Proteins were quantified by the
BCA protein assay (Pierce). An aliquot of TIF (3 mg) from the post-
mortem samples was loaded on nitrocellulose membrane, Trans-
Blot Transfer Medium (Bio-Rad), by vacuum deposition on the
Bio-Dot SF blotting apparatus (Bio-Rad). Membranes were
probed with the specific primary antibodies and then with goat
anti-rabbit or anti-mouse peroxidase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology). Blots were developed by
Immobilon Western Chemiluminescent HRP Substrate (Millipore)
on the ChemiDoc XRS system (Bio-Rad). Densitometry was done
with Progenesis PG240 v2006 software (Nonlinear Dynamics).
Immunoreactivity was normalised to the actual amount of proteins
loaded on the membrane as detected after Red Ponceau staining
(Fluka).
Immunohistochemistry
Female mice (at least four for each group) were anesthetized
with Equitensin (1% phenobarbital/4% (vol/vol) chloral hydrate,
6 mL/g, ip) and transcardially perfused with 20 mL of sodium
phosphate buffer (PBS) followed by 50 mL 4% paraformaldehyde
solution in PBS. Spinal cords were rapidly removed and post-fixed
as previously described [66]. Immunolabelling was done on
lumbar spinal cord sections (30-mm thick floating cryosections or
40-mm thick vibratome sections). Endogenous peroxidases were
inactivated by 1% hydrogen peroxide in PBS (135 mM NaCl,
2.6 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4).
The sections were incubated with 5% normal goat serum (NGS) in
PBST (PBS + 0.3% Triton X-100) 1 h at RT, then probed
overnight at 4uC in 5% NGS, PBST with a rabbit polyclonal anti-
aconitase antibody (1:500, kindly provided by Dr. L.I. Szweda).
Subsequently the sections were washed in PBS and incubated 1 h
at RT in 5% NGS, PBST with a secondary biotinylated anti-
rabbit antibody, diluted 1:200, from Vector. The secondary
antibody was revealed with a TSA amplification kit, Cy5 (Perkin
Elmer) as previously described [66]. For SOD1 labelling the
mouse monoclonal anti-human SOD1, MO62-3 (clone 1G2,
1:3000, MBL, Japan) was used and for mitochondrial labelling the
mouse monoclonal anti cytochrome oxidase subunit I antibody
(clone 1D6, 1:200, Molecular Probes) was used. Fluorescence-
labelled sections were mounted with Fluorsave (Calbiochem) and
analyzed under an Olympus Fluoview or a TCS NT Leica laser
scanning confocal microscope. Selected vibratome sections,
permeabilised with ethanol instead of Triton, were processed for
the ultrastructural detection of aconitase using a standard
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immunoperoxidase procedure using the Vectastain ABC kit
(Vector) and diaminobenzidine tetrahydrochloride (DAB) as a
chromogen. After visualization of reaction product with DAB,
sections were osmicated, dehydrated and flat-embedded in epoxy
resin. Selected areas of the embedded sections were then cut with a
razor blade and glued to blank blocks of resin for further
sectioning with an ultramicrotome. Thin sections collected on
copper grids were counterstained with lead citrate and observed
and photographed with a Zeiss 902 electron microscope.
Detection and Identification of Nitrated Proteins
TIF from WT and G93A samples were loaded on 7-cm IPG
strips (pH 3–10, non-linear) and separated by IEF as described in
the 2DE section, in duplicate. One 2D gel was stained with
SYPROH Ruby protein gel stain (Invitrogen) and the other was
transferred onto PVDF membrane (Millipore) and probed
overnight at 4uC with anti-nitrotyrosine rabbit polyclonal
antibody, provided by A.G. Estevez, or the anti-nitrotyrosine
mouse monoclonal antibody (clone HM.11; HyCult Biotechnol-
ogy). Results were visualized with the QdotH 800 goat anti-rabbit
or anti-mouse IgG conjugate antibody (Invitrogen), capturing the
images with the laser scanner Molecular Imager FX (Bio-Rad).
Nitrated protein signals of the 2D WB were localized in the 2D gel
by the specific warping algorithm of the Progenesis software and
processed for identification by peptide mass fingerprinting. No
false immunopositive spots were detected as tested by treating
membranes with sodium dithionite, as described previously [16].
Dot blot analysis of TIF of human tissues was done with anti-
nitrated HSP90 monoclonal antibody, prepared and characterized
as described [20].
NSC-34 Cell Lines
WT or G93A SOD1 expressing NSC-34 cells were obtained by
stably transfecting a NSC-34 derived line expressing the
tetracycline-controlled transactivator protein tTA with pBI-EGFP
containing WT or G93A hSOD1 cDNA cloned downstream to
the tetracycline-responsive bidirectional promoter [67] and
express similar amount of human and murine SOD1 (Figure
S5). Cell lines were kept in culture in DMEM (high glucose)
supplemented with tet-screened FBS (5%, Clontech), 1 mM
glutamine, 1 mM pyruvate, antibiotics (100 IU/mL penicillin
and 100 mg/mL streptomycin), G418 sulphate (0.5 mg/mL)
(Invitrogen) and hygromycin (0.2 mg/mL) (Invitrogen). For this
study cells were grown without doxycycline in the medium,
allowing full expression of transfected WT or G93A SOD1.
Cell Treatments
A 10-mM stock solution of MG132 (Calbiochem) was prepared
in dimethylsulfoxide and a 30-mM stock solution of L-NAME
(Sigma) in PBS. Cells were seeded at a density of 6850 cells/cm2 in
T25 flasks, and grown under standard conditions for six days, then
treated with MG132, L-NAME or both (respectively 5 mM and
300 mM final concentration). After 24 h, the cells were detached
with 1xPBS and washed once with 1xPBS, then recovered by
centrifugation at 2506g for 10 minutes. The cell pellets were
stored at 280uC until analysis of protein aggregates.
Analysis of Cellular TIF
Three cell pellets from different flasks for each genotype and
condition were independently processed to obtain the TIF. A
sample of 3 mg TIF for each condition was loaded on nitrocellulose
membrane and analyzed on the Bio-Dot SF blotting apparatus
(Bio-Rad) with the antibodies for the specific proteins, as described
for the human samples. Immunoreactivity values were multiplied
by the total TIF from each cell pellet. Total TIF is considered the
ratio of the amount of isolated TIF to the total proteins extracted.
Proteins were quantified by the BCA protein assay (Pierce).
Cytotoxicity Assay
Cell death was analyzed by quantifying extracellular lactate
dehydrogenase (LDH) activity with the cytotoxicity detection kit of
LDH (Roche Applied Science), as described [68]. For each
sample, the ratio of extracellular to intracellular LDH activities
was obtained. Results were expressed as percentages of the
untreated control cells of each cell line.
Supporting Information
Figure S1 Representative anti-ubiquitin immunoblot of TIF
from late-symptomatic G93A SOD1 and age-matched WT SOD1
mice. The same amount of TIF (30 mg) was loaded in each
immunoblot.
Found at: doi:10.1371/journal.pone.0008130.s001 (1.41 MB TIF)
Figure S2 Representative Cy-dye 2DE maps of TIF from spinal
cord of G93A SOD1 mice at 12, 17 and 26 weeks of age in
comparison with WT SOD1 mice. The same amount of protein
was loaded (75 mg) in each gel and contained a Cy3-labelled
sample (25 mg), a Cy5-labelled sample (25 mg) and the Cy2-
labelled internal standard (25 mg). Gel images were captured by
the laser scanner Molecular Imager FX (Bio-Rad). Image analysis
was done with Progenesis PG240 v2006 software (Nonlinear
Dynamics). The spots considered in the analysis were the ones
found differentially expressed in the end-stage analysis (Fig. 1 and
Table 1).
Found at: doi:10.1371/journal.pone.0008130.s002 (7.70 MB TIF)
Figure S3 Lumbar ventral horn of a non-transgenic mouse
labeled for anti-aconitase (A, green) and anti-cytochrome oxidase
(B, red). Both markers form a fine punctate labeling pattern in the
soma of motor neurons (n, nucleus) and in the neuropil. C.
Merged images show colocalization (yellow). Bar = 40 mm.
Found at: doi:10.1371/journal.pone.0008130.s003 (0.47 MB TIF)
Figure S4 Analysis of nitrated proteins in TIF of 26-week-old
WT SOD1 mice: 150 mg of TIF was loaded into the 2D gel and
transferred onto a PDVF membrane. The blot was probed with
anti-nitrotyrosine polyclonal antibody (A), after total protein
SYPRO Ruby blot staining (B). Spot numbers in (A) correspond
to proteins in Table 2.
Found at: doi:10.1371/journal.pone.0008130.s004 (5.69 MB TIF)
Figure S5 Anti-SOD1 Western blot of total protein extracts
from NSC-34 cells expressing WT or G93A SOD1. The same
amount of proteins (30 mg) was loaded in immunoblot.
Found at: doi:10.1371/journal.pone.0008130.s005 (0.90 MB TIF)
Table S1 MALDI TOF MS identification of proteins differen-
tially present in TIF from spinal cord of WT and G93A SOD1
mice.
Found at: doi:10.1371/journal.pone.0008130.s006 (0.12 MB
DOC)
Table S2 Proteins enriched in TIF of spinal cord from WT
SOD1 mice.
Found at: doi:10.1371/journal.pone.0008130.s007 (0.04 MB
DOC)
Table S3 WB of selected proteins. The proteins were measured
in TIF (aggregate) and in the soluble (soluble) fraction of spinal
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cord protein extracts from WT and G93A SOD1 mice at 26 weeks
of age.
Found at: doi:10.1371/journal.pone.0008130.s008 (0.11 MB
DOC)
Table S4 DIGE analysis of TIF from spinal cord of WT and
G93A SOD1 mice at different disease stages.
Found at: doi:10.1371/journal.pone.0008130.s009 (0.10 MB
DOC)
Table S5 Clinical and neuropathological characteristics of ALS
cases.
Found at: doi:10.1371/journal.pone.0008130.s010 (0.03 MB
DOC)
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